Novodiag™ and Amplidiag™ Easy platforms to serve both low- and high-throughput customer needs with emphasis on accessibility and affordability
Espoo, Finland – April 22, 2015 – Mobidiag Ltd, a Finnish molecular diagnostics company specializing in the development of innovative diagnostics solutions for infectious diseases, today announced the first public presentation of two new diagnostic platforms – Novodiag and Amplidiag Easy – at ECCMID 2015 in Copenhagen on April 25-28.
The entirely new Novodiag platform is a fully integrated and automated system, enabling accessible and affordable molecular testing. The platform enables fast, very easy to use and highly multiplexed on-demand molecular testing for any throughput needs. It combines advanced features, ease of use, and affordability unmatched by currently available products, and requires no dedicated molecular testing expertise. The Novodiag platform will be readied for a full commercial launch in mid-2016 to serve various testing needs in the infectious diseases space, as well as in other potential markets which are unserved by current molecular platforms.